Ferring Pharmaceuticals Adds Two Products to its Reproductive Health Portfolio in the US
14 January 2019 - - Switzerland-based biopharmaceutical company Ferring Pharmaceuticals has inked an exclusive agreement to acquire the US commercialisation rights for a generic version of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd. (Sun Pharma), the company said.

With the addition of Ganirelix, Ferring continues to offer the most complete reproductive medicine portfolio available, which includes Menopur (menotropins for injection), NOVAREL (chorionic gonadotropin for injection, USP) and Endometrin (progesterone) Vaginal Insert.

Ganirelix is a GnRH antagonist used to prevent premature luteinizing hormone surges in women undergoing fertility treatment.

On November 30, 2018, Sun Pharma received final approval from the US FDA for its Abbreviated New Drug Application for generic version of Ganirelix Acetate Injection, 250 mcg/0.5 mL.

In addition, Ferring also finalized the transaction with INVO Bioscience Inc. to acquire the exclusive US commercialization rights for the INVOcell Intravaginal Culture System, which comprises the INVOcell Culture Device and Retention Device.

The INVOcell Culture Device uses a woman's own body as an incubator during fertilization and early embryo development.

In 2015, INVO Bioscience received FDA clearance for the INVOcell IVC system, making it the first IVC system marketed in the US.

Through this acquisition, Ferring will use its resources and expertise in the field of assisted reproductive technologies to help reproductive endocrinology practices across the country expand their service offerings to include the IVC procedure, in addition to their current treatment offerings of intrauterine insemination and in vitro fertilization.

In the US, statistics show that over 1.4m women may benefit from advanced fertility treatment. However, only approximately 130,000 people begin such treatment.2

Ferring Pharmaceuticals is a biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, women's health, urology, gastroenterology, endocrinology and orthopaedics.

Ganirelix Acetate Injection is used to prevent premature ovulation during controlled ovarian stimulation.